Evaluating the Effectiveness of LACTOFOS in Constipated Patients (COSI)

University of Sao Paulo

Status and phase: Unknown; Phase 3

Conditions: Constipation

Treatments: Dietary Supplement: Symbiotic Lactofos; Dietary Supplement: Maltodextrin

Study type: Interventional

Funder types: Other

Identifiers

NCT01286376

COSI

Details and patient eligibility

About

Determine the effectiveness of symbiotic LACTOFOS containing FOS and probiotics against placebo in patients with a diagnosis of constipation, comparing the average number of weekly evacuations in 2 (two) groups for 30 days.

Full description

A prospective, randomized, double blind, parallel group. Consist of a period of 30 days of treatment with placebo or with LACTOFOS.Will study 120 patients were female with a diagnosis of constipation according to Rome III criteria for at least 3 (three) months.

The experimental group (N = 60)will receive LACTOFOS 12g/day in two doses of 6 g. The control group (N = 60)will receive a placebo (maltodextrin) from 12g/day in two shots of 6 g.

Subsequently, the patients will be classified according to the study of AGACHAN, which determined a score based on the main complaints of patients. The symptoms that included evaluation for the total score were stool frequency, difficulty / straining, pain at defecation, feeling of incomplete evacuation, abdominal pain, time taken to initiate the evacuation, type of assistance for evacuation, failed attempts / day and duration of constipation. The intensity of each symptom varied within the range of 0 to 4, with the exception of the item type of assistance for evacuation, which ranged from 0 to 2.

Constipation is classified as mild when the total sum of values (scores) vary from 00 to 10, as moderate when the sum of the values obtained vary from 11 to 20 and severe when the final sum range from 21 to 30.

Enrollment: 60 estimated patients

Sex: Female

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Females aged 18-75 years
2. A diagnosis of constipation defined by Rome III criteria
3. Ability to good communication with the investigator and agreeing to requests from the entire study
4. Patients must sign a formal consent to participate

Exclusion criteria

1. Constipation drug source
2. History or evidence of organic disease of the gastrointestinal tract such as tumors, inflammatory bowel disease, etc.. proven by radiological or endoscopic examination of the bowel (five years before and after onset of symptoms). If the investigator has doubts should request the necessary procedures, such as sigmoidoscopy, colonoscopy or edema bariatric to exclude organic disease
3. History of laxative use which in the opinion of the investigator is consistent with severe laxative dependence
4. Current History recent (12 months) of significant abuse of alcohol or drugs
5. History of malignancy in 5 (five) previous years (except basal cell carcinoma treated well or cervical carcinoma in situ)
6. Known history of cardiovascular control inappropriate and / or significant respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other illness which compromises the ability of patients to participate in the full study
7. Use of investigational drugs in the previous month or intentional use of such drugs during the study
8. Intention of regular use of other medications that affect intestinal motility and / or perceived
9. Lactose malabsorption is not treatable. If clinical suspicion of lactose intolerance, the procedure for proper diagnosis should be made to establish or exclude a diagnosis. If malabsorption is diagnosed, the patient should receive appropriate conditions of treatment

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups, including a placebo group

symbiotic

Active Comparator group

Treatment:

Dietary Supplement: Symbiotic Lactofos

placebo

Placebo Comparator group

Treatment:

Dietary Supplement: Maltodextrin